Skip to main content

Advertisement

SpringerLink
Log in

Can bisphosphonates play a role in the treatment of children with chronic kidney disease?

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

In patients with chronic kidney disease (CKD) renal osteodystrophy, in the form of either low- or high-turnover bone disease, is quite common. While renal transplantation is expected to reverse renal osteodystrophy, long-term treatment with glucocorticoids before and/or after transplantation may lead to osteoporosis instead. Osteoporosis is defined as a skeletal disease with low bone mineral density, microarchitectural deterioration, and concomitant fragility. In adults, bisphosphonates are widely used to treat osteoporosis and other diseases associated with excessive bone resorption. In pediatric CKD patients the efficacy and safety of these drugs have not yet been addressed adequately and thus no evidence-based recommendations regarding the optimal type of bisphosphonate, dosage, or duration of therapy are available. Furthermore, while in adults the determination of areal bone mineral density is sufficient to diagnose osteoporosis, this is not the case in children. Instead, in pediatric patients, careful morphological assessment of bone structure and formation is required. Indeed, data from studies with uremic rats indicated that bisphosphonates, via a deceleration of bone turnover, have the potential not only to aggravate pre-existing adynamic bone disease, but also to impair longitudinal growth. Thus, the widespread use of bisphosphonates in children with CKD should be discouraged until the risks and benefits have been carefully elucidated in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119

    Article  CAS  PubMed  Google Scholar 

  2. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105

    PubMed  Google Scholar 

  3. Mitsnefes MM (2008) Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 23:27–39

    PubMed  PubMed Central  Google Scholar 

  4. Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197

    CAS  PubMed  Google Scholar 

  5. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis—from clinical observation towards molecular understanding. Osteoporos Int 18:251–259

    CAS  PubMed  Google Scholar 

  6. Peck WA, Burckhardt P, Christiansen C, Fleisch HA, Genant HK, Gennari C, Martin TJ, Martini L, Morita R, Ogata E, Rapado A, Shulman LE, Stern PH, Young RTT (1993) Consensus Development Conference—Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am J Med 94:646–650

    Google Scholar 

  7. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141

    CAS  PubMed  Google Scholar 

  8. Ward LM, Glorieux FH (2003) The spectrum of pediatric osteoporosis. In: Glorieux FH, Pettifor JM, Jüppner H (eds) Pediatric bone biology and disease, vol 1. Elsevier Science, San Diego, pp 401–442

    Google Scholar 

  9. Grenda R (2010) Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 25:747–752

    PubMed  Google Scholar 

  10. Bianchi ML (2002) Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 70:384–390

    CAS  PubMed  Google Scholar 

  11. Leonard MB (2007) Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 119 [Suppl 2]:S166–S174

    PubMed  Google Scholar 

  12. Shaw NJ (2008) Management of osteoporosis in children. Eur J Endocrinol 159 [Suppl 1]:S33–S39

    CAS  PubMed  Google Scholar 

  13. Moe SM, Drueke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chron Kidney Dis 14:3–12

    Google Scholar 

  14. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S (2010) Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 25:769–778

    PubMed  Google Scholar 

  15. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA (2004) Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 8:357–361

    PubMed  Google Scholar 

  16. Kodras K, Haas M (2006) Effect of kidney transplantation on bone. Eur J Clin Invest 36 [Suppl 2]:63–75

    PubMed  Google Scholar 

  17. Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731

    PubMed  PubMed Central  Google Scholar 

  18. Weber LT, Mehls O (2010) Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol 25:3–5

    PubMed  Google Scholar 

  19. Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045

    CAS  PubMed  Google Scholar 

  20. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80–100

    CAS  PubMed  Google Scholar 

  21. Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9 [Suppl 4]:3–13

    CAS  PubMed  Google Scholar 

  22. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O’Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617–625

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Neven EG, De Broe ME, D’Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580–582

    CAS  PubMed  Google Scholar 

  24. Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915

    CAS  PubMed  Google Scholar 

  25. Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824

    CAS  PubMed  Google Scholar 

  26. Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356–363

    CAS  PubMed  Google Scholar 

  27. Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233

    CAS  PubMed  Google Scholar 

  28. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57–68

    CAS  PubMed  Google Scholar 

  29. Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264

    CAS  PubMed  Google Scholar 

  30. Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119 [Suppl 2]:S150–S162

    PubMed  Google Scholar 

  31. Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759

    CAS  PubMed  Google Scholar 

  32. Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577–1583

    CAS  PubMed  Google Scholar 

  33. Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H (2005) Effect of etidronate on aortic calcification and bone metabolism in calcitoriol-treated rats with subtotal nephrectomy. J Pharmacol Sci 99:89–94

    CAS  PubMed  Google Scholar 

  34. Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S (2005) Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 5:174–181

    CAS  PubMed  Google Scholar 

  35. Brown JJ, Zacharin MR (2005) Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 41:553–557

    CAS  PubMed  Google Scholar 

  36. Wright HL, McCarthy HS, Middleton J, Marshall MJ (2009) RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2:56–64

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K (2009) Osteoporosis: an age-related and gender-specific disease—a mini-review. Gerontology 55:3–12

    PubMed  Google Scholar 

  38. Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29:293–299

    CAS  PubMed  Google Scholar 

  39. Bianchi ML, Baim S, Bishop NJ, Gordon CM, Hans DB, Langman CB, Leonard MB, Kalkwarf HJ (2010) Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 25:37–47

    PubMed  Google Scholar 

  40. Leonard MB (2007) A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol 22:1815–1824

    PubMed  PubMed Central  Google Scholar 

  41. Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190

    PubMed  Google Scholar 

  42. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669–2676

    CAS  PubMed  Google Scholar 

  43. Fan SL, Cunningham J (2001) Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens 10:581–588

    CAS  PubMed  Google Scholar 

  44. Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215–222

    CAS  PubMed  Google Scholar 

  45. Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59–64

    CAS  PubMed  Google Scholar 

  46. Sellers E, Sharma A, Rodd C (1998) The use of pamidronate in three children with renal disease. Pediatr Nephrol 12:778–781

    CAS  PubMed  Google Scholar 

  47. Shaw NJ, Bishop NJ (2005) Bisphosphonate treatment of bone disease. Arch Dis Child 90:494–499

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 20:150–157

    PubMed  Google Scholar 

  49. WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129

    Google Scholar 

  50. Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, Munns C, Wenkert D, Zeitler P (2008) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 11:22–28

    PubMed  Google Scholar 

  51. Saland JM, Goode ML, Haas DL, Romano TA, Seikaly MG (2001) The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. Am J Transplant 1:243–250

    CAS  PubMed  Google Scholar 

  52. K/DOQI (2003) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201

    Google Scholar 

  53. K/DOQI (2005) Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1–S103

    Google Scholar 

  54. Christoforidis A, Printza N, Gkogka C, Siomou E, Challa A, Kazantzidou E, Kollios K, Papachristou F (2010) Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J Bone Miner Metab. doi:https://doi.org/10.1007/s00774-010-0220-1

  55. Camacho PM, Lopez NA (2008) Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med 46:1345–1357

    CAS  PubMed  Google Scholar 

  56. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92:443–449

    CAS  PubMed  Google Scholar 

  57. Singer FR, Eyre DR (2008) Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 75:739–750

    PubMed  Google Scholar 

  58. Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11:281–294

    CAS  PubMed  Google Scholar 

  59. Loud KJ, Gordon CM (2006) Adolescent bone health. Arch Pediatr Adolesc Med 160:1026–1032

    PubMed  Google Scholar 

  60. Acott PD, Wong JA, Lang BA, Crocker JF (2005) Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 20:368–373

    PubMed  Google Scholar 

  61. Kim SD, Cho BS (2006) Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 102:c81–c87

    CAS  PubMed  Google Scholar 

  62. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatol (Oxf) 44:813–818

    CAS  Google Scholar 

  63. Ward LM, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury, Rauch F, Tugwell P, Moher D (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev CD005324

  64. Fan SL, Almond MK, Ball E, Evans K, Cunningham J (2000) Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684–690

    CAS  PubMed  Google Scholar 

  65. Palmer SC, McGregor DO, Strippoli GF (2007) Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev CD005015

  66. Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T (2007) Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 22:1601–1607

    CAS  PubMed  Google Scholar 

  67. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S (2007) Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 22:1593–1600

    CAS  PubMed  Google Scholar 

  68. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241–247

    CAS  PubMed  Google Scholar 

  69. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680–688

    CAS  PubMed  Google Scholar 

  70. Bachrach LK, Ward LM (2009) Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94:400–409

    CAS  PubMed  Google Scholar 

  71. Machado CE, Flombaum CD (1996) Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 45:175–179

    CAS  PubMed  Google Scholar 

  72. Torregrosa JV, Moreno A, Mas M, Ybarra J, Fuster D (2003) Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int Suppl S88–S90

  73. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285–290

    CAS  PubMed  Google Scholar 

  74. Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M (2007) Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 47:942–950

    CAS  PubMed  Google Scholar 

  75. Beigel AE, Rienhoff E, Olbricht CJ (1995) Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 10:2266–2268

    CAS  PubMed  Google Scholar 

  76. Bergner R, Dill K, Boerner D, Uppenkamp M (2002) Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 17:1281–1285

    CAS  PubMed  Google Scholar 

  77. Buttazzoni M, Rosa Diez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L (2006) Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 11:197–200

    CAS  Google Scholar 

  78. Rauch F, Schonau E, Glorieux FH (2000) Bisphosphonates—pediatric use. Monatsschr Kinderheilkd 148:334–341

    Google Scholar 

  79. Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831–847

    CAS  PubMed  Google Scholar 

  80. Haffner D, Fischer DC (2010) Bone cell biology and pediatric renal osteodystrophy. Minerva Pediatr 62:273–284

    CAS  PubMed  Google Scholar 

  81. Fischer DC, Jensen C, Rahn A, Salewski B, Kundt G, Behets GJ, D’Haese P, Haffner D (2011) Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol 26:111–117

    PubMed  Google Scholar 

  82. Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534–540

    CAS  PubMed  Google Scholar 

  83. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D’Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University Hospital of Rostock, Ernst-Heydemann-Strasse 8, 18057, Rostock, Germany

    Dieter Haffner & Dagmar-Christiane Fischer

Authors
  1. Dieter Haffner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dagmar-Christiane Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dieter Haffner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haffner, D., Fischer, DC. Can bisphosphonates play a role in the treatment of children with chronic kidney disease?. Pediatr Nephrol 26, 2111–2119 (2011). https://doi.org/10.1007/s00467-010-1739-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1739-z

Keywords

Search

Navigation